1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
gurujx
gurujx
Articles (514) 

Weekly CFO Sales Highlight: CLB, CPHD, ALXN, RDEA, BCR

July 31, 2011 | About:

According to GuruFocus Insider Data, the largest CFO sells during the past week were: Core Laboratories N.V, CEPHEID, Alexion Pharmaceuticals Inc, Ardea Biosciences, and C.R. Bard Inc.

Core Laboratories N.V. (NYSE:CLB): EVP, CFO & Treasurer Richard L Bergmark Sold 50,000 Shares

EVP, CFO & Treasurer of Core Laboratories N.V. (NYSE:CLB) Richard L Bergmark sold 50,000 shares on 07/25/2011 at an average price of $111.76. Based in the Netherlands, Core Laboratories provides geological andenvironmental analysis services and manufactures precise measurementequipment. Core Laboratories N.v. has a market cap of $4.95 billion; its shares were traded at around $108.68 with a P/E ratio of 32.8 and P/S ratio of 6.3. The dividend yield of Core Laboratories N.v. stocks is 0.9%. Core Laboratories N.v. had an annual average earnings growth of 28.7% over the past 10 years. GuruFocus rated Core Laboratories N.v. the business predictability rank of 4.5-star.

Core Laboratories N.V. recently reported its second quarter 2011 results. For this quarter, the company posted total revenues of $225.8 million – up 13.5% from the $198.9 million prior year quarter. EPS was 90 cents compared to 71 cents prior year quarter, with a total net income of $40.45 million compared to $34.22 million last year.

CEO David M Demshur sold 200,000 shares of CLB stock on 07/27/2011 at the average price of 109.26. EVP, CFO & Treasurer Richard L Bergmark sold 50,000 shares of CLB stock on 07/25/2011 at the average price of 111.76. Richard L Bergmark owns at least 121,054 shares after this. The price of the stock has decreased by 2.76% since. Other insiders sold shares of CLB stock during the past week as well.

CEPHEID (NASDAQ:CPHD): CFO Andrew Miller Sold 50,000 Shares

CFO of CEPHEID (NASDAQ:CPHD) Andrew Miller sold 50,000 shares on 07/26/2011 at an average price of $39.67. Cepheid, Inc. develops, manufactures and markets microfluidic systems that integrate, automate and accelerate biological testing. Cepheid has a market cap of $2.33 billion; its shares were traded at around $37.76 with a P/E ratio of 755.2 and P/S ratio of 11.1.

For its second quarter 2011, CEPHEID reported total revenues of $67 million compared to $49.6 million prior year quarter. GAAP Net income for the company was $1.8 million compared to a net loss of $1.8 million last year. Non-GAAP Net income was $7.2 million compared to $2.9 million prior year quarter. Total product sales were $63.6 million compared to $48.6 million last year.

CFO Andrew Miller sold 50,000 shares of CPHD stock on 07/26/2011 at the average price of 39.67. Andrew Miller owns at least 2,500 shares after this. The price of the stock has decreased by 4.81% since. Executive VP, COO Humberto Reyes sold 325,000 shares of CPHD stock on 07/25/2011 at the average price of 39.65. Sr. VP, Regulatory Russell Enns sold 30,000 shares of CPHD stock on 07/22/2011 at the average price of 39.85.

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN): SVP & CFO Vikas Sinha Sold 26,305 Shares

SVP & CFO of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) Vikas Sinha sold 26,305 shares on 07/27/2011 at an average price of $58.33. Alexion Pharmaceuticals develops pharmaceutical products for the treatment of heart disease, and inflammation, diseases of the immune system and cancer in humans. Alexion Pharmaceuticals Inc. has a market cap of $10.44 billion; its shares were traded at around $56.8 with a P/E ratio of 68.1 and P/S ratio of 19.3.

For its second quarter 2011, Alexion Pharmaceuticals Inc. reported revenues of $185.7 million compared to $125.8 million priory year quarter. Total net income was $34.7 million – a 60% increase from $21.8 million last year. Sales of the company’s Solaris increased 48% to $185.7 million from last year.

CEO Leonard Bell sold 2,285 shares of ALXN stock on 07/27/2011 at the average price of 57.27. SVP & CFO Vikas Sinha sold 26,305 shares of ALXN stock on 07/27/2011 at the average price of 58.33. Vikas Sinha owns at least 352,103 shares after this. The price of the stock has decreased by 2.62% since. SVP. Global Commercial Ops David Hallal sold 37,427 shares of ALXN stock on 07/28/2011 at the average price of 57.33. Director Joseph A Madri sold 30,000 shares of ALXN stock on 07/27/2011 at the average price of 56.53. Other insiders sold shares of ALXN stock during the past week as well.

Ardea Biosciences Inc. (RDEA): SVP, Finance & Operations, CFO John W Beck Sold 16,000 Shares

SVP, Finance & Operations, CFO of Ardea Biosciences Inc. (RDEA) John W Beck sold 16,000 shares on 07/25/2011 at an average price of $24.46. IntraBiotics Pharmaceuticals, Inc. develops and intends to commercialize new antibacterial and antifungal drugs for the prevention or treatment of serious infectious diseases. Ardea Biosciences Inc. has a market cap of $624.1 million; its shares were traded at around $23.4 with and P/S ratio of 22.8.

Ardea Biosciences Inc. has released its first quarter 2011 results. The company reported revenues of $1.8 million compared to $3.3 million prior year quarter. Net loss during the quarter was $15.2 million compared with a net loss of $10.1 million last year.

SVP, Finance & Operations, CFO John W Beck sold 16,000 shares of RDEA stock on 07/25/2011 at the average price of 24.46. John W Beck owns at least 4,409 shares after this. The price of the stock has decreased by 4.33% since. SVP, Regulatory & Dev Ops Kimberly Manhard sold 5,000 shares of RDEA stock on 07/28/2011 at the average price of 23.56.

C.R. Bard Inc. (NYSE:BCR): Senior Vice President and CFO Todd C Schermerhorn Sold 33,400 Shares

Senior Vice President and CFO of C.R. Bard Inc. (NYSE:BCR) Todd C Schermerhorn sold 33,400 shares on 07/22/2011 at an average price of $100.5. C.R. Bard, Inc. is one of the worldwide leaders in developing, manufacturing, and supplying healthcare products that focus on Vascular, Urology, and Oncology Disease States. C.r. Bard Inc. has a market cap of $8.45 billion; its shares were traded at around $98.68 with a P/E ratio of 16.3 and P/S ratio of 3.2. The dividend yield of C.r. Bard Inc. stocks is 0.8%. C.r. Bard Inc. had an annual average earnings growth of 15.6% over the past 10 years. GuruFocus rated C.r. Bard Inc. the business predictability rank of 5-star.

During its second quarter 2011, C.R.Bard Inc. reported net loss of $47.8 million compared to a net income of $124.6 million last year. Revenues increased 7.6% to $725 million from last year.

Senior Vice President and CFO Todd C Schermerhorn sold 33,400 shares of BCR stock on 07/22/2011 at the average price of 100.5. Todd C Schermerhorn owns at least 119,481 shares after this. The price of the stock has decreased by 1.81% since.

For the complete list of stocks that Sold by their CFOs, go to: Insider Buys.

  • CEO Buys, CFO Buys: Stocks that are bought by their CEO/CFOs.
  • Insider Cluster Buys: Stocks that multiple company officers and directors have bought.
  • Double Buys:: Companies that both Gurus and Insiders are buying
  • Triple Buys: Companies that both Gurus and Insiders are buying, and Company is buying back.

» Take a Free Trial of Premium Membership


Rating: 2.3/5 (11 votes)

Comments

Please leave your comment:


GuruFocus Mobile App


User Generated Screeners


9gebbbLFG Quant Valuation I
rod1z52-Week-Low With Gurus
vinwayPEG
derdavid1
DBrizanreturn on tang assets15
James LiCurrently Profitable Sloans
yowie89Pinoy Cheap List
rael2222?????
rael2222???
rael2222??
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK